Alessandro Feo, Andrea Govetto, Prithvi Ramtohul, Néda Abraham, Diogo Cabral, Peter Y Chang, Nauman Chaudhry, Fred K Chen, Dean Eliott, Livia Faes, Rachael C Heath Jeffery, Sarah Mrejen, Marko M Popovic, Marisa G Tieger, Luca Zatreanu, SriniVas R Sadda, K Bailey Freund, Mario R Romano, David Sarraf
{"title":"Stellate Nonhereditary Idiopathic Foveomacular Retinoschisis and Central Anomalous Retinoschisis with mid-PEripheral Traction (CARPET).","authors":"Alessandro Feo, Andrea Govetto, Prithvi Ramtohul, Néda Abraham, Diogo Cabral, Peter Y Chang, Nauman Chaudhry, Fred K Chen, Dean Eliott, Livia Faes, Rachael C Heath Jeffery, Sarah Mrejen, Marko M Popovic, Marisa G Tieger, Luca Zatreanu, SriniVas R Sadda, K Bailey Freund, Mario R Romano, David Sarraf","doi":"10.1016/j.oret.2025.01.019","DOIUrl":"10.1016/j.oret.2025.01.019","url":null,"abstract":"<p><strong>Purpose: </strong>To report the clinical and multimodal imaging (MMI) findings and long-term follow-up of stellate nonhereditary idiopathic foveomacular retinoschisis (SNIFR) contiguous with midperipheral retinoschisis (MPRS) and to describe a severe SNIFR variant termed CARPET (Central Anomalous Retinoschisis with mid-PEripheral Traction).</p><p><strong>Design: </strong>Retrospective case series.</p><p><strong>Subjects: </strong>Eleven patients (15 eyes) with SNIFR contiguous with MPRS in at least 1 eye at baseline or final follow-up.</p><p><strong>Methods: </strong>Multimodal imaging features, including cross-sectional and en face macular and peripheral spectral-domain OCT and OCT angiography, were reviewed in all cases at baseline and at the final follow-up visit.</p><p><strong>Main outcome measures: </strong>Various courses (including progression, regression, or stability) of MPRS or SNIFR over time were evaluated.</p><p><strong>Results: </strong>Midperipheral retinoschisis exhibited centripetal progression to SNIFR in 5 eyes of 3 patients with follow-up of 67, 60, and 27 months, respectively, with maintenance of excellent visual acuity (range: 20/25-20/20) in 4 of these 5 eyes. In 2 eyes of 2 patients (including 1 eye with initial centripetal progression of MPRS to SNIFR), MPRS contiguous with SNIFR spontaneously resolved with long-term follow-up (77 and 25 months, respectively). Stellate nonhereditary idiopathic foveomacular retinoschisis contiguous with MPRS partially regressed after 48 months in 1 patient, and was stable after 54 months in another. A distinctive midperipheral microvasculopathy, associated with MPRS that was contiguous with SNIFR, was identified in 7 eyes of 4 patients. Finally, 3 eyes of 3 patients exhibited additional unique features, including central neurosensory detachment and outer lamellar macular hole, which were associated with significant midperipheral traction, representing a severe variant subtype of SNIFR that we refer to as CARPET. Two of these 3 eyes progressed with short-term follow-up of 6 and 2 months, respectively, whereas the schisis resolved and vision improved after pars plana vitrectomy in the third case.</p><p><strong>Conclusions: </strong>Midperipheral retinoschisis can progress to SNIFR over multiple years of follow-up. Stellate nonhereditary idiopathic foveomacular retinoschisis with MPRS can also spontaneously resolve or remain stable. Midperipheral retinoschisis can additionally be complicated by a midperipheral inner retinal microvasculopathy. Finally, CARPET may represent a unique and severe variant form of SNIFR driven by midperipheral vitreoretinal traction and associated with significant vision loss.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"High-Risk Retinoblastoma Based on International Classification Systems: Analysis of 1362 Eyes.","authors":"Deepthi E Kurian, Swathi Kaliki, Carol L Shields","doi":"10.1016/j.oret.2025.01.020","DOIUrl":"10.1016/j.oret.2025.01.020","url":null,"abstract":"<p><strong>Purpose: </strong>To determine the predictive value of International Intraocular Retinoblastoma Classification schemes and the American Joint Committee on Cancer (AJCC) classification for histopathological high-risk features (HRFs).</p><p><strong>Design: </strong>Multicentric international collaborative retrospective case series.</p><p><strong>Subjects: </strong>One thousand three hundred and sixty-two patients with retinoblastoma from 16 centers and 11 countries.</p><p><strong>Intervention: </strong>Primary enucleation; adjuvant therapy in patients with HRF.</p><p><strong>Main outcome measures: </strong>High-risk retinoblastoma defined as 1 or more HRF (anterior segment involvement, massive choroidal invasion, minor choroidal infiltration with prelaminar optic nerve invasion, retrolaminar or resected optic nerve cut end involvement, scleral or microscopic extrascleral infiltration); metastasis-free survival (MFS).</p><p><strong>Results: </strong>Of the 1362 patients, 751 (55.1%) had HRF. According to the International Classification of Retinoblastoma (ICRB) (Philadelphia vs. Los Angeles [LA]) versus Children's Oncology Group (COG) classification schemes, the positive predictive value (PPV) of group D eyes for HRF was 42.0% versus 35.1% versus 43.2%, respectively, and that for group E eyes was 58.5% versus 59.0% versus 59.5%, respectively. Comparing group D versus group E eyes, there was higher mean number of HRF (standard deviation, range) among group E eyes using the ICRB Philadelphia (0.7 [0.9, 0.0-6.0] vs. 1.3 [1.7, 0.0-9.0], P < 0.001), ICRB LA (0.6 [0.8, 0.0-6.0] vs. 1.3 [1.7, 0.0-9.0], P < 0.001) and COG (0.8 [1.2, 0.0-7.0] vs. 1.3 [1.6, 0.0-8.0], P < 0.001) classifications. The PPV for HRF was above 55% for AJCC clinical tumor (cT) group cT3a with increments through cT3e to 72.3%. An agreement between ICRB Philadelphia versus ICRB LA, ICRB LA versus COG, and ICRB Philadelphia versus COG was 0.9, 0.8, and 0.8, respectively (P < 0.001). Metastasis-free survival rates and overall survival rates were also comparable between all intraocular retinoblastoma classification schemes but better stratified within the AJCC scheme.</p><p><strong>Conclusions: </strong>All intraocular retinoblastoma classification schemes predict HRF and MFS equally. Group E includes a wide spectrum equivalent to the AJCC group cT3. Uniform grouping with subcategorization of group E might improve risk stratification. We propose that everyone across the retinoblastoma world henceforth adopts the AJCC classification for all reporting and publishing.</p><p><strong>Financial disclosure(s): </strong>The authors have no proprietary or commercial interest in any materials discussed in this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jennifer I Lim, Manuel J Amador, Dilsher S Dhoot, Avni Finn, Samantha Fraser-Bell, Kara Gibson, Oluwatobi O Idowu, Rahul N Khurana, Paolo Lanzetta, Tai-Chi Lin, Florie A Mar, Andreas Pollreisz, Aleksandra Rachitskaya, Patricio G Schlottmann, Yannan Tang, Timothy Y Y Lai
{"title":"Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema.","authors":"Jennifer I Lim, Manuel J Amador, Dilsher S Dhoot, Avni Finn, Samantha Fraser-Bell, Kara Gibson, Oluwatobi O Idowu, Rahul N Khurana, Paolo Lanzetta, Tai-Chi Lin, Florie A Mar, Andreas Pollreisz, Aleksandra Rachitskaya, Patricio G Schlottmann, Yannan Tang, Timothy Y Y Lai","doi":"10.1016/j.oret.2025.01.017","DOIUrl":"10.1016/j.oret.2025.01.017","url":null,"abstract":"<p><strong>Purpose: </strong>To compare anatomic biomarkers on spectral-domain OCT between faricimab, a dual angiopoietin-2 (Ang-2)/VEGF-A inhibitor, and aflibercept in a pooled analysis of results from the YOSEMITE/RHINE trials in diabetic macular edema (DME).</p><p><strong>Design: </strong>YOSEMITE/RHINE (NCT03622580/NCT03622593) were identical, randomized, double-masked, active comparator-controlled, 100-week phase III noninferiority trials.</p><p><strong>Participants: </strong>Adults with visual acuity loss due to center-involving DME.</p><p><strong>Methods: </strong>Patients were randomized 1:1:1 to faricimab 6.0 mg every 8 weeks (Q8W), faricimab 6.0 mg treat-and-extend (T&E), or aflibercept 2.0 mg Q8W for 100 weeks. The T&E up to every 16 weeks dosing regimen was based on central subfield thickness (CST) and best-corrected visual acuity changes.</p><p><strong>Main outcome measures: </strong>Post hoc analyses comparing faricimab with aflibercept on CST change; the proportion of eyes with an absence of intraretinal fluid (IRF), subretinal fluid, or both IRF and subretinal fluid or achieving a CST <280 μm at key timepoints during the trials; time to first absence of IRF; and time to first achieving CST <280 μm.</p><p><strong>Results: </strong>In total, 1891 patients were enrolled across YOSEMITE/RHINE (n = 632 faricimab Q8W; n = 632 faricimab T&E; n = 627 aflibercept). There were greater CST reductions from baseline with both faricimab dosing regimens compared with aflibercept over the 100 weeks (adjusted means and area-under-the-curve analysis). Higher proportions of eyes achieved an absence of IRF with faricimab Q8W (58%-63%) and faricimab T&E (44%-49%) versus aflibercept (36%-41%) at weeks 92 to 100. In eyes with IRF at baseline, the median time to first absence of IRF was achieved 40 weeks earlier with faricimab versus aflibercept. The proportion of eyes achieving a CST <280 μm at weeks 92 to 100 was 70% to 74% with faricimab Q8W, 61% to 65% with faricimab T&E, and 61% to 63% with aflibercept. In eyes with CST ≥280 μm at baseline, the median time to first instance of CST <280 μm was achieved 16 weeks earlier with faricimab versus aflibercept.</p><p><strong>Conclusions: </strong>Dual Ang-2/VEGF-A inhibition with faricimab resulted in greater and faster improvements in anatomic outcomes compared with aflibercept at key timepoints over the pooled YOSEMITE/RHINE trials.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143365350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexander M Rusakevich, Jennifer P Tingley, Kareem Moussa
{"title":"Inadvertent Intralenticular Bevacizumab Injection.","authors":"Alexander M Rusakevich, Jennifer P Tingley, Kareem Moussa","doi":"10.1016/j.oret.2024.12.024","DOIUrl":"https://doi.org/10.1016/j.oret.2024.12.024","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lorenzo Ferro Desideri, Martin Zinkernagel, Rodrigo Anguita
{"title":"Foveal Cavitations by High-resolution OCT after Acute Macular Neuroretinopathy.","authors":"Lorenzo Ferro Desideri, Martin Zinkernagel, Rodrigo Anguita","doi":"10.1016/j.oret.2024.12.022","DOIUrl":"https://doi.org/10.1016/j.oret.2024.12.022","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael A Singer, Dilraj S Grewal, Preston O'Brien, Fabiana Silva, Weiming Du, Guruprasad B, Hadi Moini, Mark R Barakat
{"title":"Impact of Baseline Vision on Outcomes in Diabetic Macular Edema in VISTA/VIVID.","authors":"Michael A Singer, Dilraj S Grewal, Preston O'Brien, Fabiana Silva, Weiming Du, Guruprasad B, Hadi Moini, Mark R Barakat","doi":"10.1016/j.oret.2025.01.016","DOIUrl":"10.1016/j.oret.2025.01.016","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maria Vittoria Cicinelli MD , Prithvi Ramtohul MD , Lorenzo Bianco MD , Ugo Introini MD , Francesco Bandello MD , K. Bailey Freund MD , Maurizio Battaglia Parodi MD
{"title":"Prevalence, Features, and Outcomes of Type 1 Neovascularization in Eyes with Angioid Streaks","authors":"Maria Vittoria Cicinelli MD , Prithvi Ramtohul MD , Lorenzo Bianco MD , Ugo Introini MD , Francesco Bandello MD , K. Bailey Freund MD , Maurizio Battaglia Parodi MD","doi":"10.1016/j.oret.2024.08.002","DOIUrl":"10.1016/j.oret.2024.08.002","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aimed to delineate the characteristics, prevalence, and outcomes of neovascularization (NV), particularly aneurysmal type 1 NV, in patients with angioid streaks (AS) secondary to pseudoxanthoma elasticum (PXE), and to introduce a clinical classification based on multimodal imaging.</div></div><div><h3>Design</h3><div>Retrospective longitudinal cohort study.</div></div><div><h3>Participants</h3><div>Eighty-five patients (168 eyes) with AS secondary to PXE at 2 tertiary referral centers.</div></div><div><h3>Methods</h3><div>Data collection included demographic, medical, and ocular histories. Diagnostic methods comprised fundus photography, autofluorescence, indocyanine green angiography, OCT, and OCT angiography.</div></div><div><h3>Main Outcome Measures</h3><div>Prevalence of type 1 NV, visual acuity (VA), risk of exudation.</div></div><div><h3>Results</h3><div>Type 1 NV was identified in 127 eyes (76%), with 85 of these (67%) showing exclusively type 1 NV. These lesions often originated around the disc, at sites of Bruch membrane dehiscences, and followed the path of AS, extending to the macula in 101 eyes (80%). Despite 65% of type 1 NV remaining nonexudative, 35% evolved into exudative over 5 years, and 11 eyes experienced midperipheral subretinal hemorrhages. Aneurysmal dilations, observed in 57% of eyes, substantially increased exudation risk (hazard ratio = 3.86, <em>P</em> = 0.02). Despite treatment, VA significantly deteriorated in exudative type 1 NV (<em>P</em> = 0.02). Type 2 NV, detected in 42 eyes (33%), often coexisted with type 1 NV and was associated with poorer visual outcomes and higher rates of macular atrophy. A classification of AS was developed, ranging from empty AS (stage 0, no NV) to advanced NV (stage 3, both type 1 and type 2 NV).</div></div><div><h3>Conclusions</h3><div>Type 1 NV predominates in AS. Although predominantly nonexudative, its progression correlates with substantial visual impairment, similar to the deficits observed with type 2 NV. Aneurysmal type 1 NV poses a significant exudation risk, underscoring the need for vigilant monitoring.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 2","pages":"Pages 166-179"},"PeriodicalIF":4.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141913628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexandra Thaler BA, Thomas M. Catapano BS, Carol L. Shields MD
{"title":"Adenoma of the Retinal Pigment Epithelium Arising from Congenital Hypertrophy","authors":"Alexandra Thaler BA, Thomas M. Catapano BS, Carol L. Shields MD","doi":"10.1016/j.oret.2024.06.014","DOIUrl":"10.1016/j.oret.2024.06.014","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 2","pages":"Page e10"},"PeriodicalIF":4.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}